Eli Lilly and Co (LLY) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Lilly's Investor Day Highlights Stronger Than Expected Portfolio, Leading to an FVE Increase

Sector Director Damien Conover

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA | Dec 16, 2021

Eli Lilly hosted an investor day highlighting a better-than-expected outlook, leading us to increase our fair value estimate to $235 from $215. While the company looks very well positioned for industry-leading growth over the next five years, we continue to view the stock as modestly overvalued. Nevertheless, the firm’s robust pipeline and broad portfolio across several therapeutic areas continue to support a strong wide moat.

Read Full Analysis

Company Profile

Business Description

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact

Lilly Corporate Center
Indianapolis, IN, 46285

T +1 317 276-2000

hern_kevin_r@lilly.com

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Sep 30, 2021

Fiscal Year End Dec 31, 2020

Stock Type Classic Growth

Employees 19,500

Related

Stock Strategist Industry Reports

Big Biopharma Capital Allocation Supports Undervalued Stocks and Dividend Growth

Our top two picks in this wide-moat industry are poised to benefit.

Stock Strategist Industry Reports

What Litigation Risk Means for Big Pharma and Biotech Valuations

As we incorporate ESG factors into our analysis, we see a manageable headwind.

Stock Analyst Update

FDA Issues New Warnings on JAK Drug Class

The warnings put pressure on key drugs for AbbVie, Pfizer, and Eli Lilly, but we don’t see any major fair value estimate impacts.

Stock Analyst Update

Lilly Posts Solid Q2 Led by Top Drug Trulicity

The firm's wide moat is supported by a strong portfolio and late-stage pipeline.

These Sectors Performed Best and Worst in the Pandemic

We look at the industries for those most affected by social-distancing and stay-at-home orders.

Sachin Nagarajan

Stock Strategist Industry Reports

COVID-19 Sales Have No Major Impact on Drug and Vaccine Manufacturers We Cover

However, the biopharma industry's ability to adapt and innovate to treat disease reinforces our moat ratings.

Stock Strategist Industry Reports

Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021

We expect quickly declining sales potential after that, however.

Stock Analyst Update

Eli Lilly Provides Strong Outlook and Positive Updates

The wide-moat firm continues to show significant innovation. We plan to increase our fair value estimate.

Stock Strategist Industry Reports

Implementation of Trump's Drug-Pricing Orders Unlikely

We don't foresee any impact on pharma companies' moats or valuations.

Stock Strategist Industry Reports

We Still Expect a Strong U.S. Economic Recovery

Neither the U.S. election outcome nor the coronavirus third wave will derail it.

Preston Caldwell

Stock Strategist Industry Reports

Slow Burn Likely Until Coronavirus Vaccines Are Widely Available

Resurgences in outbreaks make it clear that ending the pandemic will require more than diagnostic testing, contact tracing, and social distancing.

Stock Strategist Industry Reports

Innovation Supports Growth at Big Pharma/Big Biotech Companies

Moats and returns on invested capital look stable for companies with a solid list of pipeline drugs.

Stock Analyst Update

Drug Pricing Executive Orders Not Likely to Affect FVEs

We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.

Stock Strategist Industry Reports

Timeline Accelerates for COVID-19 Drug Development

Three new vaccines for coronavirus look poised for emergency use authorization in the U.S. this fall.

Stock Strategist

Positive Data Boosts Outlook for Lilly

The wide-moat drugmaker's growth prospects are improving.

Stock Strategist Industry Reports

Coronavirus Vaccine Progress Accelerates

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

Stock Strategist Industry Reports

Coronavirus Has Limited Impact on Big Pharma and Big Biotech

Moats, valuations, and dividends look attractive in the market pullback.

Stock Analyst Update

Recent Drug Launches Support Strong Quarter for Lilly

We have raised our fair value estimate based on an improving outlook.

The Week Ahead: Earnings Heat Up With Apple, Amazon, and Facebook

Reports are also due for Visa, Exxon, Verizon, and many more.

Stock Strategist Industry Reports

How ESG Risk Affects Pharma and Biotech Moats and Valuations

Morningstar and Sustainalytics offer complementary methodologies.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.